Ren He Biotechnology responds to the request for a price reduction for Benalurothiopeptide and is included in the medical insurance list: Choosing proactive strategic options according to the development stage.

Recently, the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List was officially announced. This time, the National Basic Medical Insurance list has added 114 new drugs and removed 29 drugs. It was reported earlier that Renhui Biotechnology's GLP-1 drug exenatide has been removed. Regarding the "removal" statement, Renhui Biotechnology told reporters on December 12th that this was the result of a careful evaluation based on the company's overall strategic development plan, commercial layout, and comprehensive cost considerations. They voluntarily submitted an application to the National Medical Insurance Administration in July 2025. Renhui Biotechnology expressed sincere thanks to the National Medical Insurance Administration for their support of innovative drug companies and the exenatide version for lowering blood sugar. This adjustment is a proactive strategic choice by the company based on its development stage. In the short term, the company hopes to more accurately serve patients in need in the field of reproductive weight reduction, create social benefits, optimize resource allocation, and achieve sustainable development.